Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | CDC7 | O00311 | 4/20 | 0.57 |
| ▸ | DBF4 | Q9UBU7 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FHIT | P49789 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7091737 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2CDC7DBF4ALDH1A1CYP1A2 | |
| SCHEMBL2648928 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2CDC7DBF4ALDH1A1CYP1A2 | |
| SCHEMBL24753892 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2CDC7DBF4ALDH1A1CYP1A2 | |
| SCHEMBL286068 | 0.82 | CDC7 (0.60) | SMN1; SMN2CDC7DBF4ALDH1A1CYP1A2 | |
| SCHEMBL16933028 | 0.82 | CDC7 (0.60) | SMN1; SMN2CDC7DBF4ALDH1A1CYP1A2 | |
| SCHEMBL13593795 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2CDC7DBF4ALDH1A1CYP1A2 | |
| SCHEMBL6476591 | 0.81 | CDC7 (0.59) | SMN1; SMN2CDC7DBF4ALDH1A1CYP1A2 | |
| SCHEMBL274346 | 0.81 | CDC7 (0.59) | SMN1; SMN2CDC7DBF4ALDH1A1CYP1A2 | |
| SCHEMBL33099 | 0.80 | KDM4E (0.43) | SMN1; SMN2ALDH1A1MAPTHPGDGAA | |
| SCHEMBL5911684 | 0.80 | CDC7 (0.55) | SMN1; SMN2CDC7DBF4ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 726 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024615-A | Preparation method and application of algal polysaccharide derivative | 马强 | 2023-11-10 | — | — | CN | claimed |
| CN-101265275-B | Diethyl 4-{6-[5-(2-chloro-6-methylanilinoformacyl)-thiazolyl-2-amino]-2-methylpyrimidin-4}-piperazin-1-phosphate | INST MATERIA MEDICA CAMS | 2012-09-05 | — | — | CN | claimed |
| WO-2011104540-A1 | ONE STEP PROCESS FOR THE PREPARATION OF CAPECITABINE | GENERICS [UK] LIMITED (GB) | 2011-09-01 | — | — | WO | claimed |
| CN-101323629-B | 4-{6-[5-(2-chlorinde-6- methylaniline formyl)-thiazole-2-amido]-2-methyl pyrimidine-4}-piperazine-1- diethyl methylphosphate | JIANGSU CHIA TAI TIANQING PHAR | 2011-08-17 | — | — | CN | claimed |
| CN-101323629-A | 4-{6-[5-(2-chlorinde-6- methylaniline formyl)-thiazole-2-amido]-2-methyl pyrimidine-4}-piperazine-1- diethyl methylphosphate | INST MATERIA MEDICA CAMS (CN) | 2008-12-17 | — | — | CN | claimed |
| CN-101265275-A | Diethyl 4-{6-[5-(2-chloro-6-methylanilinoformacyl)-thiazolyl-2-amino]-2-methylpyrimidin-4}-piperazin-1-phosphate | INST MATERIA MEDICA CAMS (CN) | 2008-09-17 | — | — | CN | claimed |
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| US-20250340886-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-11-06 | — | — | US | disclosed |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| US-20250296928-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
| US-5120752-A | N-(1-(20(3-pyridyloxy)phenyl)cyclopropyl) alkyl-N-hydroxyurea compounds, antiinflammatory agents | ABBOTT LABORATORIES (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0436199-A1 | Cyclopropyl derivative lipoxygenase inhibitors | ABBOTT LABORATORIES (US) | 1991-07-10 | — | — | EP | disclosed |
| US-4324899-A | 2-Amino-5-cyanothiazoles and their preparation | EASTMAN KODAK COMPANY (US) | 1982-04-13 | — | — | US | disclosed |
| US-4160764-A | AZO ATTACHED TO AMINO AND ALKOXY SUBSTITUTED PHENYL, DYEING AND PRINTING CELLULOSE ACETATES, POLYAMIDES, POLYURETHANES, POLYOLEFINS, POLYCARBONATES, POLYESTERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-10 | — | — | US | disclosed |
| US-4056523-A | SULFONAMIDO SUBSTITUTED | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | SMN1; SMN2 3452/4885CDC7 4337/4885DBF4 4624/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | SMN1; SMN2 3372/4885CDC7 247/4885DBF4 708/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | SMN1; SMN2 566/4885CDC7 2635/4885DBF4 3113/4885 |
| US-20250296928-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | SIK3, SIK1, SIK2 | SMN1; SMN2 3631/4885CDC7 245/4885DBF4 2740/4885 |
| US-20250340886-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | SIK3, SIK1, SIK2 | SMN1; SMN2 3539/4885CDC7 248/4885DBF4 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.